Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 344articles · 30d
- 1+ day agolatest article
- Aug 14, 2026earliest in window
- 92%with images
- 291avg words
- Economy, Business & Finance 200
- Medical 159
- Health & Wellness 159
- Business & Industrial 146
- Finance & Business 135
- Health 74
- Science & Technology 53
- Science & Nature 34
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
1+ day, 20+ hour ago (373+ words) Allarity Acquisition Corp. may pursue an initial business combination in any industry, sector or geographic region. Jesper Hoiland, a current board member of Allarity and a former EVP and President of Novo Nordisk, will serve as Chairman of the board…...
Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline
2+ day, 22+ hour ago (429+ words) BioSpace Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline CAMBRIDGE, England--(BUSINESS WIRE)--Clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as Chief…...
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
2+ day, 22+ hour ago (133+ words) Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first…...
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
2+ day, 18+ hour ago (140+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
Alto Neuroscience Announces Participation in Upcoming September 2026 Investor Conferences
3+ day, 18+ hour ago (237+ words) BioSpace Alto Neuroscience Announces Participation in Upcoming September 2026 Investor Conferences MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--$anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced…...
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - September 9, 2026
3+ day, 19+ hour ago (444+ words) BioSpace bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - September 9, 2026 BIAF continues to be listed and traded on Nasdaq SAN ANTONIO--(BUSINESS WIRE)--$BIAF #BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the…...
Tenpoint Therapeutics to Participate in Upcoming Investor Conferences and Medical Meetings
3+ day, 19+ hour ago (200+ words) BioSpace Tenpoint Therapeutics to Participate in Upcoming Investor Conferences and Medical Meetings LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced participation…...
Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities
3+ day, 21+ hour ago (363+ words) PARMA, Italy--(BUSINESS WIRE)--Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 ("H1 2026"). Performance across therapeutic areas and regions Chiesi reported revenues of €1.89 billion, representing growth…...
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
3+ day, 22+ hour ago (303+ words) A new cancer biotech has dawned as Solstice Oncology launches with a massive $225 million Series A fundraising that will be used to advance a CTLA-4 antibody from China’s Harbour BioMed. Solstice CEO Caroline Loew said the mission will be to…...
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
4+ day, 7+ hour ago (212+ words) BioSpace Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet…...